3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Head & Neck
1
Conditions
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
6
Prostatic Neoplasms
4
Breast Neoplasms
4
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Melanoma
2
Glioblastoma
2
Brain Neoplasms
2
Advanced Solid Tumor
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Ulnar Neuropathies
1
Triple Negative Breast Neoplasms
1
Solid Tumor, Adult
1
Prostatic Hyperplasia
1
Peripheral Lung Tumor
1
Pain
1
Non-Muscle Invasive Bladder Neoplasms
1
Non Squamous Lung Cancer
1
Neuroma
1
Multiple Myeloma
1
Mucositis
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leiomyoma
1
Keratosis, Actinic
1
Hyperthermia
1
Glioma
1
Interventions
Radiotherapy
5
angiotensin I (1-7)
4
Cisplatin
4
Injections
3
RRx-001
2
Fibroblast Growth Factor 7
2
tempol
1
hydrated silica gel-based toothpaste
1
golotimod
1
brilacidin
1
apraglutide
1
amlexanox
1
aluminum hydroxide, magnesium hydroxide, drug combination
1
Xylitol
1
Water
1
Therapeutics
1
Radiotherapy, Intensity-Modulated
1
Lidocaine
1
Drug Therapy
1
Diphenhydramine
1
Betaine
1
2-(3',4'-dihydroxyphenyl-1-azo)benzimidazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mucositis
×
Therapeutics
×
Clear all
NCT04046250
2023-08-25
TK112690
Tosk, Inc.
Phase 2
Completed
22 enrolled
10 charts